SPONSOR
InSightec
Total Trials
3
Recruiting
3
Phases
Phase 3
Conditions studied: Alzheimer DiseaseBrain TumorNon Small Cell Lung CancerTremor Associated With Tremor Dominant Parkinson's Disease
InSightec is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Alzheimer Disease, Brain Tumor, Non Small Cell Lung Cancer, Tremor Associated With Tremor Dominant Parkinson's Disease.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — InSightec
How many clinical trials has InSightec sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by InSightec, of which 3 are actively recruiting participants. These trials cover conditions including Alzheimer Disease, Brain Tumor, Non Small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does InSightec research focus on?
InSightec clinical trials span Alzheimer Disease, Brain Tumor, Non Small Cell Lung Cancer, Tremor Associated With Tremor Dominant Parkinson's Disease. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a InSightec clinical trial?
To participate in a InSightec trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all InSightec trials with current recruitment status updated daily.
Clinical Trials by InSightec
NCT03671889
Recruiting
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Alzheimer Disease
NCT05317858 Phase 3
Recruiting
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Brain Tumor
NCT04991831
Recruiting
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
Tremor Associated With Tremor Dominant Parkinson's Disease
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology